Literature DB >> 9989931

Effects of various amino acid 256 mutations on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase function and their role in the cellular adaptive response to thapsigargin.

M Yu1, J Lin, M Khadeer, Y Yeh, G Inesi, A Hussain.   

Abstract

Upon direct selection of mammalian cells for resistance to thapsigargin (TG), a potent inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ transport ATPase (SERCA), the ATPase can acquire specific mutations at amino acid position 256 (aa256). In particular, Phe256 --> Leu and Phe256 --> Ser substitutions can occur upon TG selection, with each substitution resulting in a SERCA that is 4- to 5-fold resistant to TG inhibition (M. Yu et al., J. Biol. Chem. 273, 3542-3546, 1998). We have now identified a third substitution, i.e., Phe256 --> Val, that occurs when the Chinese hamster lung fibroblast cell line DC-3F is selected for TG resistance. Although the Phe256 --> Val substitution at codon 256 results in a SERCA whose enzymological properties in terms of Ca2+ transport and ATP hydrolysis are essentially similar to that of wild-type (wt) SERCA, the mutant enzyme is more than 40-fold resistant to TG inhibition. To analyze further the role of aa256 in TG-SERCA interactions, mutational analysis of this particular residue was also carried out. Of all the mutations introduced, only the Phe256 --> Glu substitution interferes with expression of the ATPase. The Phe256 --> Arg substitution does not interfere with SERCA expression, but the resulting enzyme is totally inactive. In terms of sensitivity of the various mutants to TG, maximal reduction in the ATPase's affinity for TG occurs with amino acid substitutions containing branched side chains, i.e. with the Phe256 --> Val, Phe256 --> Ile, and Phe256 --> Thr mutants. Since a corresponding Phe is conserved in the Na+, K+-ATPase which is not sensitive to TG, our findings suggest that this amino acid provides stabilization of the stalk segment with respect to the membrane interface, thereby optimizing specific interactions of TG with neighboring S3 residues (L. Zhong and G. Inesi, J. Biol. Chem. 273, 12994-12998, 1998). It is likely that a relatively high frequency of codon 256 mutations favor the aa256 mutants as a specific adaptive response to TG selection. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989931     DOI: 10.1006/abbi.1998.1049

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  12 in total

1.  Ca(2+) transients and Ca(2+) waves in purkinje cells : role in action potential initiation.

Authors:  P A Boyden; J Pu; J Pinto; H E Keurs
Journal:  Circ Res       Date:  2000-03-03       Impact factor: 17.367

Review 2.  What the structure of a calcium pump tells us about its mechanism.

Authors:  A G Lee; J M East
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

3.  Structure/activity relationship of thapsigargin inhibition on the purified Golgi/secretory pathway Ca2+/Mn2+-transport ATPase (SPCA1a).

Authors:  Jialin Chen; Joren De Raeymaecker; Jannik Brøndsted Hovgaard; Susanne Smaardijk; Ilse Vandecaetsbeek; Frank Wuytack; Jesper Vuust Møller; Jan Eggermont; Marc De Maeyer; Søren Brøgger Christensen; Peter Vangheluwe
Journal:  J Biol Chem       Date:  2017-03-06       Impact factor: 5.157

4.  Structural role of countertransport revealed in Ca(2+) pump crystal structure in the absence of Ca(2+).

Authors:  Koji Obara; Naoyuki Miyashita; Cheng Xu; Itaru Toyoshima; Yuji Sugita; Giuseppe Inesi; Chikashi Toyoshima
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

5.  Effects of high-affinity inhibitors on partial reactions, charge movements, and conformational States of the Ca2+ transport ATPase (sarco-endoplasmic reticulum Ca2+ ATPase).

Authors:  Francesco Tadini-Buoninsegni; Gianluca Bartolommei; Maria Rosa Moncelli; Daniel M Tal; David Lewis; Giuseppe Inesi
Journal:  Mol Pharmacol       Date:  2008-01-22       Impact factor: 4.436

6.  Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.

Authors:  Matteo Marchesini; Andrea Gherli; Anna Montanaro; Laura Patrizi; Claudia Sorrentino; Luca Pagliaro; Chiara Rompietti; Samuel Kitara; Sabine Heit; Claus E Olesen; Jesper V Møller; Monia Savi; Leonardo Bocchi; Rocchina Vilella; Federica Rizzi; Marilena Baglione; Giorgia Rastelli; Caterina Loiacono; Roberta La Starza; Cristina Mecucci; Kimberly Stegmaier; Franco Aversa; Donatella Stilli; Anne-Marie Lund Winther; Paolo Sportoletti; Maike Bublitz; William Dalby-Brown; Giovanni Roti
Journal:  Cell Chem Biol       Date:  2020-05-07       Impact factor: 8.116

7.  Preexisting domain motions underlie protonation-dependent structural transitions of the P-type Ca2+-ATPase.

Authors:  Eli Fernández-de Gortari; L Michel Espinoza-Fonseca
Journal:  Phys Chem Chem Phys       Date:  2017-04-12       Impact factor: 3.676

8.  Inhibitors of SERCA and mitochondrial Ca-uniporter decrease velocity of calcium waves in rat cardiomyocytes.

Authors:  G Landgraf; F N Gellerich; M H P Wussling
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

9.  Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity.

Authors:  Ronan Jambou; Axel Martinelli; João Pinto; Simonetta Gribaldo; Eric Legrand; Makhtar Niang; Nimol Kim; Lim Pharath; Béatrice Volnay; Marie Therese Ekala; Christiane Bouchier; Thierry Fandeur; Pedro Berzosa; Agustin Benito; Isabel Dinis Ferreira; Cynthia Ferreira; Pedro Paulo Vieira; Maria das Graças Alecrim; Odile Mercereau-Puijalon; Pedro Cravo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

10.  Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line.

Authors:  Karen Wagner-Souza; Juliana Echevarria-Lima; Louise A P Rodrigues; Marcelo Reis; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.